Table 2.
Non-invasive ventilation treatment among the study population, including non-invasive pressure support ventilation (PSV) and high-flow non-invasive continuous positive airway pressure (CPAP)
| Characteristic | Study population 60 (100) |
|---|---|
| n. (%) | 60 (100) |
| CPAP Treatment | 40 (67) |
| CPAP Generator | |
| High-flow Venturi | 23 (38) |
| Ventilator | 15 (25) |
| Boussignac Mask | 2 (3.3) |
| CPAP interface | |
| Helmet | 28 (70) |
| Nasal Mask | 6 (15) |
| Face mask | 6 (15) |
| CPAP Initial PEEP, median (IQR) | 8 (8–10) |
| CPAP Initial FiO2, median (IQR) | 50 (50–100) |
| PSV Treatment | 20 (33) |
| PSV interface | |
| Face mask | 15 (75) |
| Nasal Mask | 3 (15) |
| Helmet | 2 (10) |
| PSV Initial PEEP, median (IQR) | 5 (5–8) |
| PSV Initial PS, median (IQR) | 15 (10–20) |
| PSV Initial FiO2, median (IQR) | 50 (29–60) |
n: number. PEEP: positive end expiratory pressure; FiO2: fraction of inspired oxygen; PS: pressure support; IQR: interquartile range.